Sorrento announced the release of a series of new SARS-CoV-2 master protease (MPRO) inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2 variants of concern (including Omicron) – QNT Press Release

[ad_1]

• Representative of the novel M^Dear Inhibitor series, MPI8, dual inhibition M^Dear And cathepsin L, a key virus entry enzyme with high potency and selectivity.
• Sorrento has evaluated other analogs in the series to develop an oral antiviral drug for the treatment of patients infected with existing and emerging SARS-CoV-2 related variants (including Omicron).
• A promising candidate in the series, with unique characteristics different from SARS-CoV-2 M^Dear Inhibitors published by others have been systematically evaluated and advanced to the late preclinical stage.

San Diego, December 5, 2021 (Global News Agency)-Sorrento Therapeutics (NASDAQ:SRNE, “Sorrento”)) today announced a series of new SARS-CoV-2 M peer-reviewed^Dear Inhibitors with effective activity against both types of M^Dear Cathepsin L is a key host enzyme for SARS-CoV-2 to enter the host cell. It was written by Dr. Wenshe Ray Liu, a professor at Texas A&M University.

The complete manuscript is available at: https://pubmed.ncbi.nlm.nih.gov/34242492/

SARS-CoV-2 main protease (M^Dear) Is a key enzyme in the virus life cycle, including virus entry, replication and packaging.Meter^pressureOh It is highly conserved among all the SARS CoV-2 variants found, and has been identified as a key target for the development of broad-spectrum antiviral drugs. In addition, experimental evidence shows that certain host proteases can trigger the SARS-CoV-2 spike protein, which is used for virus packaging, interaction with ACE2, and virus entry into the host. These include two serine proteases, furin and transmembrane protease serine 2 (TMPRSS2) and the cysteine ​​protease cathepsin L. Small molecule drugs that inhibit furin, TMPRSS2 and cathepsin L have been shown to inhibit SARS-CoV-2 replication. In this publication, MPI8, the representative analogue of the series, proved that M^Dear And cathepsin L have high potency and selectivity (IC₅₀ The value of M^Dear And cathepsin L are 105 nM and 1.2 nM, respectively). Sorrento collaborated with Professor Liu’s laboratory at Texas A&M University to evaluate the analogs in the series to develop an oral anti-COVID drug. A promising analogue with characteristics different from the currently reported SARS-CoV-2 M^Dear Inhibitors have been systematically evaluated and advanced to the late preclinical stage. “We are very happy to be with Professor Liu’s team in…

The full story can be found on Benzinga.com

[ad_2]

Source link